This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Anthrax	Not applicable	<p><i>In vitro</i> and mouse studies suggest that vesicles produced by <i>Bacillus anthracis</i> could help guide the design of vaccines. In mice challenged with <i>B. anthracis</i>, vesicle-immunized animals survived a median of 13 days, whereas adjuvant-immunized mice survived a median of 2 days ($p < 0.05$). Next steps include identifying the vesicle components that elicit the protective antibody responses.</p> <p>Emergent BioSolutions Inc. markets BioThrax anthrax vaccine adsorbed (AVA) and has a recombinant protective antigen (rPA) in Phase II testing. SparVax, an rPA anthrax vaccine from PharmAthene Inc., is in Phase II testing. Green Cross Corp. has the anthrax vaccine GC1109 in Phase II testing, and Integrated Biopharma Inc. has an anthrax vaccine in Phase I testing.</p> <p>SciBX 3(41); doi:10.1038/scibx.2010.1233 Published online Oct. 21, 2010</p>	Unpatented; available for licensing	<p>Rivera, J. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Oct. 18, 2010; doi:10.1073/pnas.1008843107</p> <p>Contact: Arturo Casadevall, Albert Einstein College of Medicine of Yeshiva University, Bronx, N.Y. e-mail: casadeva@aecom.yu.edu</p>